Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$86.29 USD
-0.43 (-0.50%)
Updated Oct 21, 2024 04:00 PM ET
After-Market: $86.29 0.00 (0.00%) 4:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$86.29 USD
-0.43 (-0.50%)
Updated Oct 21, 2024 04:00 PM ET
After-Market: $86.29 0.00 (0.00%) 4:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Zacks News
Gilead Sciences (GILD) Stock Moves -0.31%: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $76.80, marking a -0.31% move from the previous day.
Time for Gilead Sciences-Heavy ETFs?
by Sanghamitra Saha
Bank of America expects the Gilead Sciences to jump about 30%, as quoted on CNBC.
Nurix (NRIX) Stock Increases 9% in a Month: Here's Why
by Zacks Equity Research
The upside in Nurix's (NRIX) shares can be attributed to the company's recently signed collaboration with Seagen (SGEN) to develop a new class of medicines for cancer.
Gilead's (GILD) Trodelvy Combo Shows Promise in NSCLC Study
by Zacks Equity Research
Gilead's (GILD) breast cancer drug Trodelvy, in combination with Keytruda, shows positive data in a phase II lung cancer study.
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $73.94 in the latest trading session, marking a -0.4% move from the prior day.
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $76.65, marking a +0.22% move from the previous day.
Gilead (GILD) Gets FDA Nod for Veklury for Hepatic Impairment
by Zacks Equity Research
Gilead's (GILD) anti-viral treatment Veklury gets FDA approval for the treatment of COVID-19 in patients with mild, moderate or severe hepatic impairment.
The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics
by Zacks Equity Research
Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics are part of the Zacks top Analyst Blog.
Biotech Stock Roundup: REGN Up on Approval, APLS, NVAX Gain on Updates & More
by Zacks Equity Research
Regulatory updates from Regeneron (REGN) and Apellis (APLS) are in focus in the biotech sector.
Top Stock Reports for Merck, Philip Morris & QUALCOMM
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Philip Morris International Inc. (PM) and QUALCOMM Incorporated (QCOM).
Gilead's (GILD) Leukemia Study Progress Put on Clinical Hold
by Zacks Equity Research
Gilead (GILD) faces a setback as the FDA puts a partial clinical hold on enrolling new patients in studies evaluating magrolimab for treating AML in the United States.
Biotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & More
by Zacks Equity Research
Regulatory updates from Galecto (GLTO) and Sonnet BioTherapeutics Holdings (SONN) are in focus in the biotech sector.
Gilead (GILD), Tentarix To Develop Cancer, Inflammation Therapies
by Zacks Equity Research
Gilead (GILD) enters into a deal with Tentarix Biotherapeutics to discover and develop novel therapies for cancer and inflammation.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Gilead's (GILD) Q2 Earnings Miss, Revenues Beat on Oncology
by Zacks Equity Research
Gilead's (GILD) Q2 earnings miss on litigation charges while revenues beat on strong oncology and HIV franchise.
Gilead (GILD) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Gilead Sciences (GILD) Q2 Earnings Lag Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of -16.25% and 2.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Gilead (GILD) Gears Up to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its second-quarter 2023 results.
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $77.19, marking a -0.05% move from the previous day.
Biotech Stock Roundup: BIIB, GSK's Q2 Earnings, KOD Faces Setback & More
by Zacks Equity Research
Earnings updates from Biogen (BIIB) and GSK (GSK) are in focus in the biotech sector.
Should SPDR Russell 1000 Yield Focus ETF (ONEY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ONEY
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $77.23, marking a -0.55% move from the previous day.
Gilead (GILD) Ends Myelodysplastic Syndromes Study on Magrolimab
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) discontinues phase III ENHANCE study, evaluating the potential of magrolimab as a treatment for higher-risk myelodysplastic syndromes, due to futility based on a planned analysis.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $78.96, moving +0.95% from the previous trading session.